Outset Medical outlines 5%–9% revenue growth for 2026 with next-gen Tablo launch and gross margin expansion

Q4 2025 Management View Leslie Trigg, President, CEO & Chairman, reported that 2025 was "a year of progress and transformation at Outset Medical," highlighting substantial cost reductions and ...

Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned

Detailed price information for Outset Medical Inc (OM-Q) from The Globe and Mail including charting and trades.
Seeking Alpha

Outset Medical, Inc. (OM) Q4 2025 Earnings Call Transcript

Good day, and thank you for standing by. Welcome to the Outset Medical Q4 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I will now ...
Nasdaq

OM Stock Gains on FDA Clearance for Next-Gen Tablo Dialysis System

Outset Medical, Inc. OM recently announced that its next-generation Tablo hemodialysis system has received 510(k) clearance, marking a key regulatory milestone for the company. The clearance positions ...